Most Read Articles
22 May 2015
A highly selective M3 antagonist developed for treating overactive bladder (OAB).

Solifenacin succinate improves urinary incontinence in Parkinson’s disease patients with overactive bladder

01 May 2015
Solifenacin succinate improves urinary incontinence in Parkinson’s disease patients with overactive bladder (OAB), according to a double-blind, randomised, placebo-controlled, 3-site study with an open-label extension phase. Improvement in the number of micturitions per 24 hours (p = 0.03) and decrease in the number of urinary incontinence episodes per 24 hours (p=0.01) were observed with solifenacin treatment.

Related MIMS Drugs

Editor's Recommendations
Most Read Articles
22 May 2015
A highly selective M3 antagonist developed for treating overactive bladder (OAB).